Introduction This open-label pilot study aimed to investigate the efficacy of canakinumab in
colchicine-resistant familial Mediterranean fever (FMF) patients. Method Patients with one or …

Objectives To evaluate the long-term efficacy and safety of canakinumab to treat patients
with colchicine-resistant familial Mediterranean fever (crFMF) during Epoch 4 (weeks 41 to …

Objective Approximately 30–45% of patients with familial Mediterranean fever (FMF) have
been reported to have attacks despite colchicine treatment. Currently, data on the treatment …

Objective We aimed to present our single-center real-life experience of canakinumab use in
adult patients with familial Mediterranean fever (FMF). Methods Data were derived from the …

Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory
disease, is characterized by recurrent self-limited attacks of fever and serositis. Between 5 …

Objective. To assess the efficacy and safety of the interleukin-1β (IL-1β) inhibitor
canakinumab in all adolescent and adult patients with familial Mediterranean fever (FMF) …

Objective Familial Mediterranean fever (FMF) is the most common inherited monogenic
autoinflammatory disease worldwide. It is caused by loss-of-function mutations in the MEFV …

Abstract Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory
disorder. In most patients, treatment with colchicine can prevent attacks of fever and …

İntroduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease
characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) …

Objective Approximately 10%–20% of patients with familial Mediterranean fever (FMF) show
an inadequate response to colchicine. In our cohort study, patients with FMF with or without …